Emma Råsmark Roepke

Dr. Emma Råsmark Roepke


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2017 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
EREmma Råsmark Roepke
Emma Råsmark Roepke
LMLeif Matthiesen
Leif Matthiesen
RRRebecca Rylance
Rebecca Rylance
OCOle Bjarne Christiansen
Ole Bjarne Christiansen

30 March 2018 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
PDF file
EREmma Råsmark Roepke
Emma Råsmark Roepke
MHMargareta Hellgren
Margareta Hellgren
RHRagnhild Hjertberg
Ragnhild Hjertberg
LBLennart Blomqvist
Lennart Blomqvist
LMLeif Matthiesen
Leif Matthiesen
ASAnnika Strandell
Annika Strandell
Introduction: Medical treatment of women with idiopathic recurrent pregnancy loss is controversial. The objective was to assess the effects of different treatments on live birth rates and complications in women with unexplained recurrent pregnancy loss.Material and methods: We searched MEDLINE, Embase and the Cochrane Library, and identified 1415 publications. This systematic review included 21 randomized controlled trials regarding acetylsalicylic acid, low‐molecular‐weight heparin, progesterone, intravenous immunoglobulin or leukocyte immune therapy in women with three or more consecutive miscarriages of unknown cause. The study quality was assessed and data was extracted independently by at least two authors.Results: No significant difference in live birth rate was found when acetylsalicylic acid was compared with low‐molecular‐weight heparin or with placebo. Meta‐analyses of low‐molecular‐weight heparin vs. control found no significant differences in live birth rate [risk ratio (RR) 1.47, 95% CI 0.83–2.61]. Treatment with progesterone starting in the luteal phase seemed effective in increasing live birth rate (RR 1.18, 95% CI 1.09–1.27) but not when started after conception. Intravenous immunoglobulin showed no effect on live birth rate compared with placebo (RR 1.07, 95% CI 0.91–1.26). Paternal immunization compared with autologous immunization showed a significant difference in outcome (RR 1.8, 95% CI 1.34–2.41), although the studies were small and at high risk of bias.Conclusion: The literature does not allow advice on any specific treatment for idiopathic recurrent pregnancy loss, with the exception of progesterone starting from ovulation. We suggest that any treatment for recurrent pregnancy loss should be used within the context of a randomized controlled trial.

6 January 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EREmma Råsmark Roepke
Emma Råsmark Roepke
Ole Bjarne ChristiansenOle Bjarne Christiansen
Ole Bjarne Christiansen
KKKarin Källén
Karin Källén
Stefan R. HanssonStefan R. Hansson
Stefan R. Hansson
Recurrent pregnancy loss (RPL), defined as three or more consecutive miscarriages, is hypothesized to share some of the same pathogenic factors as placenta-associated disorders. It has been hypothesized that a defect implantation causes pregnancy loss, while a partially impaired implantation may lead to late pregnancy complications. The aim of this retrospective register-based cohort study was to study the association between RPL and such disorders including pre-eclampsia, stillbirth, small for gestational age (SGA) birth, preterm birth and placental abruption. Women registered with childbirth(s) in the Swedish Medical Birth Register (MFR) were included in the cohort. Pregnancies of women diagnosed with RPL (exposed) in the National Patient Register (NPR), were compared with pregnancies of women without RPL (unexposed/reference). Obstetrical outcomes, in the first pregnancy subsequent to the diagnosis of RPL (n = 4971), were compared with outcomes in reference-pregnancies (n = 57,410). Associations between RPL and placental dysfunctional disorders were estimated by odds ratios (AORs) adjusting for confounders, with logistic regression. RPL women had an increased risk for pre-eclampsia (AOR 1.45; 95% CI; 1.24–1.69), stillbirth <37 gestational weeks (GWs) (AOR 1.92; 95% CI; 1.22–3.02), SGA birth (AOR 1.97; 95% CI; 1.42–2.74), preterm birth (AOR 1.46; 95% CI; 1.20–1.77), and placental abruption <37 GWs (AOR 2.47; 95% CI; 1.62–3.76) compared with pregnancies by women without RPL. Women with RPL had an increased risk of pregnancy complications associated with placental dysfunction. This risk population is, therefore, in need of improved antenatal surveillance.

23 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EREmma Råsmark Roepke
Emma Råsmark Roepke
VBValentina Bruno
Valentina Bruno
ENE. Nedstrand
E. Nedstrand
RBR. Boij
R. Boij
CSC. Petersson Strid
C. Petersson Strid
JEJ. Ernerudh
J. Ernerudh
Low-molecular-weight heparin (LMWH) is widely used to treat recurrent pregnancy loss (RPL) because of its anti-coagulant effects. Although in vitro studies have suggested additional immunological effects, these are debated. We therefore investigated whether LMWH could modulate immune responses in vivo during pregnancy of women with unexplained RPL. A Swedish open multi-centre randomised controlled trial included 45 women treated with tinzaparin and 42 untreated women. Longitudinally collected plasma samples were obtained at gestational weeks (gw) 6, 18, 28 and 34 and analysed by multiplex bead technology for levels of 11 cytokines and chemokines, chosen to represent inflammation and T-helper subset-associated immunity. Mixed linear models test on LMWH-treated and untreated women showed differences during pregnancy of the Th1-associated chemokines CXCL10 (p = 0.01), CXCL11 (p < 0.001) and the Th17-associated chemokine CCL20 (p = 0.04), while CCL2, CCL17, CCL22, CXCL1, CXCL8, CXCL12, CXCL13 and IL-6 did not differ. Subsequent Student’s t-test showed significantly higher plasma levels of CXCL10 and CXCL11 in treated than untreated women at gw 28 and 34. The consistent increase in the two Th1-associated chemokines suggests a potential proinflammatory and unfavourable effect of LMWH treatment during later stages of pregnancy, when Th1 immunity is known to disrupt immunological tolerance.

1 May 2019 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
EREmma Råsmark Roepke
Emma Råsmark Roepke
OCOle Bjarne Christiansen
Ole Bjarne Christiansen
Stefan R. HanssonStefan R. Hansson
Stefan R. Hansson
Background: The Swedish National Patient Registry (NPR) is a nationwide registry that is used extensively for epidemiological research. Using the NPR, we recently found a recurrent pregnancy loss (RPL) incidence of 650/100,000 (0.65%) pregnant women in Sweden. It is of great importance that the quality of the coding is good and reliable in order to use NPR data for research. To specifically study RPL in Sweden, a general validation of this diagnosis in the NPR is needed. Objective: To validate the diagnosis of RPL, defined as ≥3 consecutive miscarriages before 22 gestational weeks, recorded in the NPR and assess how registered miscarriages were verified clinically (ultrasound or urine/serum hCG) by reviewing the medical records. Materials and methods: In a cohort of 6,852 women diagnosed with RPL in Sweden, during 2003–2012, a total of 238 complete medical records from 38 hospitals were reviewed. A power calculation estimated that 228 medical records had to be reviewed for a positive predictive value (PPV) of 85% (95% CI) with a power of 90%. The ICD-10 diagnoses used for RPL were N96.9 and O26.2. Results: The diagnosis of RPL was confirmed in 202 out of 238 medical records resulting in a PPV of 85% (95% CI 78–89%) out of which 59% were verified with ultrasound whereas 35% were verified only by urine/serum hCG. Conclusion: The Swedish NPR is a valuable tool for epidemiological research. We found a high PPV of RPL in the NPR, supporting the use of these data for future research.

25 June 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EREmma Råsmark Roepke
Emma Råsmark Roepke
VBValentina Bruno
Valentina Bruno
ENE. Nedstrand
E. Nedstrand
RBR. Boij
R. Boij
CSC. Petersson Strid
C. Petersson Strid
JEJ. Ernerudh
J. Ernerudh
An amendment to this paper has been published and can be accessed via a link at the top of the paper.